Carbohydrate vaccines for the immunotherapy of cancer

Drug News and Perspectives

Volumn 13, Issue 8, 2000, Pages 463-470

  Lloyd, K O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOHYDRATE; CARRIER PROTEIN; EPITOPE; GANGLIOSIDE; GANGLIOSIDE GM2; GLYCOCONJUGATE; KEYHOLE LIMPET HEMOCYANIN; MUCIN; OLIGOSACCHARIDE; PROTEIN STN; PROTEIN TF; TN ANTIGEN; UNCLASSIFIED DRUG;

BLOOD GROUP ABO SYSTEM; BLOOD GROUP LEWIS SYSTEM; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; GLYCOSYLATION; HUMAN; NONHUMAN; REVIEW;

EID: 0034510548     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Carbohydrate vaccines that induce antibodies against cancer 1. Rationale
2. Molecular characteristics of tumor antigens
3. Tumor-associated carbohydrate antigens
4. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens
5. Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies
6. Immune and non-immune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells
7. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study
8. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn
9. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma
10. Solid-phase synthesis of oligosaccharides and glycoconjugates by the glycal assembly method: A five year retrospective
11. Glycals in organic synthesis: The evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence
12. Solid-phase chemical-enzymatic synthesis of glycopeptides and oligosac-charides
13. A general synthesis of model glycoproteins: Coupling of alkenyl glycosides to proteins, using reductive ozonolysis followed by reductive amination with sodium cyanoborohydride
14. Vaccines prepared with sialyl-TN and sialyl-Tn trimers using the 4-(maleimido-methyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells
15. Michael addition as the key step in the syntheses of sialyloligosaccharide-protein conjugates from N-acryloylated glycopyranosylamines
16. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors
17. Vaccination of breast cancer patients (pts) with no evidence of disease (NED) with sialyl Tn cluster (sTn(c))-keyhole limpet hemocyanin (KLH) conjugate plus adjuvant QS-21: Preliminary results
18. Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: The preparation of a glycopeptide-based vaccine for clinical trials against prostate cancer
19. Synthetic carbohydrate vaccines: Synthesis and immunogenicity of Tn antigen conjugates
20. Probing cell surface "glycoarchitecture" through total synthesis. Immunological consequences of a human blood group determinant in a clustered mucin-like context
21. Efficient syntheses of core 1, core 2, core 3 and core 4 building blocks for SPS of mucin O-glycopeptides based on the N-Dts-method
22. Synthesis and characterisation of highly glycosylated glycopeptides with Tn-antigenic structures corresponding to human glycophorin A
23. Plasmodium falciparum polyoximes: Highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein
24. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin
25. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2
26. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
27. Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice
28. Phase 1 trial of immunological adjuvant QS-21 with a GM2 gangliosidekeyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
29. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice
30. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases
31. Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: Implication for the development of human-derived cancer vaccines
32. An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice
33. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
34. Immunogenicity of melanoma-associated gangliosides in cancer patients
35. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
36. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
37. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans
38. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21
39. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer
40. New applications of the n-pentenyl glycoside method in the synthesis and immunoconjugation of fucosyl GM1: A highly tumor-specific antigen associated with small cell lung carcinoma
41. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients
42. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
43. Immunization of ovarian cancer patients with a synthetic Lewisy-protein conjugate vaccine: A phase I trial
44. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma
45. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: Isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens